Edition:
United States

Starpharma Holdings Ltd (SPL.AX)

SPL.AX on Australia Stock Exchange

0.69AUD
24 Mar 2017
Change (% chg)

$0.03 (+4.55%)
Prev Close
$0.66
Open
$0.65
Day's High
$0.69
Day's Low
$0.65
Volume
106,439
Avg. Vol
379,883
52-wk High
$0.88
52-wk Low
$0.59

Latest Key Developments (Source: Significant Developments)

Starpharma says it was granted qualified infectious disease product and fast track designation for vivagel by FDA
Wednesday, 11 Jan 2017 05:21pm EST 

Starpharma Holdings Ltd :granted qualified infectious disease product (qidp) and fast track designation for vivagel® bv by US Food and Drug Administration (FDA)..  Full Article

Starpharma signs exclusive license and supply agreement in China
Wednesday, 20 Jul 2016 11:10pm EDT 

Starpharma Holdings Ltd : Signs exclusive license and supply agreement with Shenyang sky and land latex for manufacture and sale of vivagel condoms .  Full Article

Starpharma Holdings licences VivaGel BV to Aspen for ANZ
Thursday, 3 Mar 2016 06:41pm EST 

Starpharma Holdings Ltd:Starpharma licences vivagel bv to Aspen for anz.Says signing of a license and supply agreement with Aspen Pharmacare Australia pty ltd.Says agreemnt for the sales and marketing of vivagel bv in Australia and New Zealand (anz).Says commercial terms of the agreement remain confidential.  Full Article

Starpharma signs mou for Vivagel Condom in China
Tuesday, 15 Dec 2015 04:45pm EST 

Starpharma:Starpharma signs mou for Vivagel Condom in China.Says signed a memorandum of understanding (mou) with a Chinese company who is a major provider of condoms to the Chinese government.Says Starpharma will work with its partner to proceed with the regulatory process in preparation for market launch.  Full Article

Starpharma Holdings announces EU marketing approval granted for Vivagel BV
Wednesday, 23 Sep 2015 08:09pm EDT 

Starpharma Holdings Ltd:EU marketing approval granted for Vivagel BV.Says approval for the treatment and rapid relief of Bacterial Vaginosis (BV) including symptoms.Says the approval allows for the marketing of Vivagel BV in the European economic area.Says discussions regarding marketing rights for Vivagel BV are already underway.EU approval will be used as basis for obtaining rapid regulatory and marketing approvals in other countries that recognise EU approval.  Full Article

Starpharma signs drug delivery license with AstraZeneca
Monday, 7 Sep 2015 01:40am EDT 

Starpharma Holdings Ltd:Says it has signed a licensing agreement with Starpharma for the use of its DEP ( (reg) ) drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound on signature, and with potential for follow on compounds directed at a defined family of targets.Says under the agreement it will receive a signature payment of $2 million (A$2.9 million), and is also eligible to receive potential development, launch and sales milestones for the first AstraZeneca DEP ( (reg) ) product of $124 million (A$177 million).  Full Article

More From Around the Web

BRIEF-Starpharma signs license for vivagel condom in Iran

* Signing of a license and supply agreement with koushan pharmed for sales and marketing rights to vivagel condom in Iran Source text for Eikon: Further company coverage: